Spruce Street Capital LP Buys New Shares in Corvus Pharmaceuticals, Inc. $CRVS

Posted by George Bondi on Aug 25th, 2026

Spruce Street Capital LP purchased a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 231,585 shares of the company’s stock, valued at approximately $3,459,880,000. Corvus Pharmaceuticals makes up 0.7% of Spruce Street Capital LP’s holdings, making the stock its 29th largest holding. Spruce Street Capital LP owned 0.28% of Corvus Pharmaceuticals as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. The Manufacturers Life Insurance Company raised its stake in Corvus Pharmaceuticals by 481.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 101,779 shares of the company’s stock valued at $1,489,000 after purchasing an additional 84,282 shares during the period. DCF Advisers LLC bought a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $9,524,000. Blue Owl Capital Holdings LP purchased a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at approximately $9,092,000. Renaissance Technologies LLC purchased a new stake in Corvus Pharmaceuticals during the 1st quarter valued at approximately $1,190,000. Finally, Avidity Partners Management LP bought a new stake in shares of Corvus Pharmaceuticals during the first quarter valued at approximately $1,682,000. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS opened at $14.09 on Tuesday. The company has a market capitalization of $1.19 billion, a P/E ratio of -23.10 and a beta of 0.87. Corvus Pharmaceuticals, Inc. has a one year low of $5.28 and a one year high of $26.95. The stock has a 50 day moving average price of $14.10 and a 200-day moving average price of $14.81.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). As a group, equities analysts predict that Corvus Pharmaceuticals, Inc. will post -0.79 EPS for the current fiscal year.

Insider Activity at Corvus Pharmaceuticals

In other Corvus Pharmaceuticals news, Director David Scott Moore acquired 21,700 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $11.53 per share, with a total value of $250,201.00. Following the purchase, the director directly owned 21,700 shares of the company’s stock, valued at approximately $250,201. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 19.70% of the stock is owned by insiders.

Analysts Set New Price Targets

CRVS has been the subject of a number of research reports. Wall Street Zen lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Finally, LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.33.

Get Our Latest Research Report on CRVS

About Corvus Pharmaceuticals

(Free Report)

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.